News | May 08, 2024
WACKER expands production capacity for biopharmaceuticals in San Diego
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
New solvent-free micronization technology expanded at the Darmstadt site in Germany
The proposed facility is expected to be operational around January, 2027
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Additional capacity broadens Grace’s fine chemical capabilities for API production
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
NEIAFMR to be developed as the national hub for folk medicine
Development services for gene and cell therapies is planned to begin first in 2025
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Subscribe To Our Newsletter & Stay Updated
